FDAMA off-label data provisions likely to be revisited in drug user fee reauthorization -- Hutt.
This article was originally published in The Gray Sheet
FDAMA OFF-LABEL JOURNAL REPRINT CLAUSE MAY BE REVISITED IN PDUFA III DISCUSSIONS in 2002, Covington & Burling attorney Peter Barton Hutt told attendees of a Management Forum seminar on the FDA Modernization Act in London Jan. 19. Debate over the off-label promotions clause will "likely be reopened" when discussions begin for a third reauthorization of the Prescription Drug User Fee Act because the clause "will not be as useful as Congress intended," Hutt maintained. The provisions are "very unsatisfactory [and] very restrictive."
You may also be interested in...
A congressional hearing tentatively scheduled to take place by mid-2001 will examine the ability of FDA to approve breakthrough medical technology in a timely fashion, according to the medical device trade group AdvaMed.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.